Robert K Hills

Real world data and the art of maintenance therapy

Robert K Hills, R. Hills, 2019, British journal of haematology.

Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.

Robert K Hills, R. Hills, A. Burnett, 2011, Blood.

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Adam J Mead, Robert K Hills, A. Mead, 2008, Blood.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Torsten Haferlach, Claude Preudhomme, Wolfgang Kern, 2018, Blood.

Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease.

Adam J Mead, Robert K Hills, A. Mead, 2008, Blood.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Yashma Patel, Robert K Hills, Hassan Farah, 2016, The New England journal of medicine.

Balancing treatment allocations by clinician or center in randomized trials allows unacceptable levels of treatment prediction

Richard Gray, Robert K Hills, Keith Wheatley, 2009, Journal of evidence-based medicine.

Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.

Lars Kjeldsen, Robert K Hills, Keith Wheatley, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.

Robert K Hills, R. Hills, N. Russell, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.